IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.

Trial Details

NCT ID
NCT06092892
Phase
PHASE2
Sponsor
Alice Chung
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Breast Surgery (BCS or mastectomy) with TAD/SNB
  • Adjuvant Radiation Therapy
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Pasadena, California, United States|34.14778,-118.14452
  • Tarzana, California, United States|34.17334,-118.55397

Key Eligibility Criteria

  • Women age ≥ 45
  • Clinical T1-2N0 ER+ invasive breast cancer
  • US detected biopsy proven axillary nodal disease
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →